Immutep (NASDAQ:IMMP - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.
Immutep Stock Performance
Shares of NASDAQ IMMP traded up $0.01 on Friday, reaching $1.74. 46,848 shares of the company's stock traded hands, compared to its average volume of 208,701. Immutep has a 12 month low of $1.32 and a 12 month high of $2.80. The business's 50 day simple moving average is $1.78 and its two-hundred day simple moving average is $1.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.25 and a quick ratio of 18.25.
Hedge Funds Weigh In On Immutep
Institutional investors and hedge funds have recently made changes to their positions in the business. OLD Mission Capital LLC bought a new position in shares of Immutep during the fourth quarter valued at approximately $36,000. Two Sigma Securities LLC bought a new stake in shares of Immutep during the fourth quarter valued at approximately $74,000. Jane Street Group LLC increased its position in shares of Immutep by 14.7% during the first quarter. Jane Street Group LLC now owns 51,574 shares of the biotechnology company's stock valued at $91,000 after acquiring an additional 6,617 shares in the last quarter. Finally, ABC Arbitrage SA bought a new stake in shares of Immutep during the fourth quarter valued at approximately $152,000. Institutional investors own 2.32% of the company's stock.
About Immutep
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Further Reading
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
